Furthermore, BLF1 downregulated critical proteins such as MYCN and CDK4 and increased caspase 3/7 activity threefold, highlighting its potential for targeted NB therapy with reduced side effects compared to conventional treatments (64). The gene discussed is MYCN; the disease is neuroblastoma.